Partnerships for the Development of Tools to Advance Therapeutic Discovery for Select Antibiotic-Resistant Gram-Negative Bacteria (R01 Clinical Trial Not Allowed)

US Dept. of Health & Human Services: National Institutes of Health (NIH)

View website Save this grant

Next deadline: Jul 21, 2024 (Letter of inquiry)

Later deadlines: Aug 20, 2024 (Full proposal)

Grant amount: Up to US $750,000

Fields of work: Pharmacology Microbiology

Applicant type: Organizations

Funding uses: Research

Location of project: Anywhere in the world

Location of residency: Anywhere in the world

Overview:

NOTE:

  • Letter of Inquiry (Letter of Intent) - This is due 30 days prior to the application due date (due by 5:00 pm local time of applicant organization).
  • The following deadline applies to the standard grant application (due by 5:00 pm local time of applicant organization):
    • August 20, 2024

Partnerships for the Development of Tools to Advance Therapeutic Discovery for Select Antibiotic-Resistant Gram-Negative Bacteria (R01 Clinical Trial Not Allowed)

Purpose

The purpose of this Notice of Funding Opportunity (NOFO) is to support milestone-driven projects focused on developing and utilizing novel predictive models, assays, tools, and/or platforms based on penetration and efflux of small molecules to facilitate therapeutic discovery for select Gram-negative bacterial pathogens: carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales (CRE), and multidrug-resistant Pseudomonas aeruginosa.

Research Objectives and Scope

The objective of this NOFO is to support milestone-driven projects focused on developing and utilizing novel predictive models, assays, tools, and/or platforms aimed at gaining a better understanding of the rules and compound properties that govern the penetration and efflux of drug-like small molecules into Gram-negative bacterial pathogens. This NOFO also supports the preclinical development of novel Gram-negative antibacterial therapeutics based on the tools and models hereby developed.

Applications must focus on one or more of the following Gram-negative bacterial pathogens: carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales (CRE), and/or MDR Pseudomonas aeruginosa. Projects should complete assay/tool/model development prior to the end of the third year of the project period and initiate discovery activities to demonstrate its utility in supporting a corresponding medicinal chemistry program to generate a lead chemical series with demonstrated activity against one or more targeted Gram-negative bacteria. This NOFO will also support subsequent preclinical development of a promising lead antibacterial.

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.

US Dept. of Health & Human Services: National Institutes of Health (NIH)
FUNDER

Your history with this funder
0
SAVED OPPORTUNITIES
No saved opportunities from this funder yet
FUNDER NOTES
Save this opportunity to add notes...
CONTACTS
Save this opportunity to add contacts...

Other Funding Opportunities from Us Dept. Of Health & Human Services: National Institutes Of Health (Nih)

Forecasted Funding Opportunities from Us Dept. Of Health & Human Services: National Institutes Of Health (Nih) help icon

Don't miss out on other good fit funders!

Get personalized grant recommendations, tracking and more by creating a free 14-day account.

No credit card required.
instrumentl testimonial face

"Winning 30% more grants thanks to Instrumentl was a huge morale boost. My confidence continues to grow."

Linda Rucker, Grant Writer

This page was last reviewed April 03, 2024 and last updated April 03, 2024